Silencing of immune activation with methotrexate in patients with COVID-19

J Neurol Sci. 2020 Aug 15:415:116942. doi: 10.1016/j.jns.2020.116942. Epub 2020 May 25.

Authors

Farinaz Safavi¹, Avindra Nath²

Affiliations

¹ Section of Infections of the Nervous System, National Institute of Neurological Disorders and stroke, National Institutes of Health, Bethesda, MD, United States of America.
² Section of Infections of the Nervous System, National Institute of Neurological Disorders and stroke, National Institutes of Health, Bethesda, MD, United States of America. Electronic address: natha@ninds.nih.gov.

No abstract available

Publication types

Editorial
Research Support, N.I.H., Intramural

MeSH terms

Betacoronavirus / drug effects
COVID-19
Coronavirus Infections / complications
Coronavirus Infections / drug therapy*
Coronavirus Infections / immunology*
Humans
Immunosuppressive Agents / therapeutic use*
Inflammation / complications
Inflammation / drug therapy*
Inflammation / immunology
Methotrexate / therapeutic use*
Pandemics
Pneumonia, Viral / complications
Pneumonia, Viral / drug therapy*
Pneumonia, Viral / immunology*
SARS-CoV-2

Substances

Immunosuppressive Agents
Methotrexate